Neurofibromatosis type 1 (NF1) is a genetic condition that causes tumors to grow along nerves in the skin, brain, and other parts of the body. These tumors are usually noncancerous (benign), but they ...

The risks of 4 types of skin cancers were investigated among patients who have neurofibromatosis type 1, a multisystem autosomal dominant genetic syndrome characterized by loss of neurofibromin. Basal ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Gomekli is the first treatment of its kind to be ...

Neurofibromatosis type 1 (NF1) is a genetically inherited disorder that manifests in a broad spectrum of clinical features including dermatological, neurological, skeletal and notably, ocular ...

GOMEKLI is the first FDA-approved treatment for adult and pediatric NF1-PN, showing effective tumor reduction and manageable safety. SpringWorks Therapeutics has announced the FDA approval of GOMEKLI ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Mirdametinib is an investigational mitogen-activated ...

Mirdametinib received FDA approval for NF1 patients aged 2 and older, showing efficacy in reducing PN volume and improving quality of life. Conditional European approval was granted for mirdametinib, ...

The US Food and Drug Administration (FDA) has approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.) for certain adult and pediatric patients with neurofibromatosis type 1 (NF1). Specifically ...

A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has studied alterations in the KRAS gene in colorectal cancer by combining genomic ...

The FDA has approved selumetinib (Koselugo, AstraZeneca) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). With the new regulatory decision, ...

Rapid NF1-PN growth and symptom progression are typical during early childhood, but disease progression can occur at any time. Neurofibromatosis type 1 (NF1) is a genetic condition that causes changes ...